Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 13/20 | 0.43 |
| ▸ | DRD2 | P14416 | 7/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7842113 | 1.00 | DRD4 (0.43) | DRD4DRD2DRD3OPRM1ADRA1D | |
| SCHEMBL16218248 | 0.80 | CHRM2 (0.47) | DRD4DRD2DRD3OPRM1ADRA1D | |
| SCHEMBL6965093 | 0.78 | OPRM1 (0.42) | DRD4DRD2DRD3OPRM1ADRA1D | |
| SCHEMBL10819399 | 0.77 | DRD4 (0.54) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL7245093 | 0.77 | SLC18A3 (0.55) | DRD4DRD2DRD3OPRM1 | |
| SCHEMBL6198248 | 0.75 | DRD4 (0.42) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL7120829 | 0.75 | DRD4 (0.48) | DRD4DRD2DRD3OPRM1CHRM2 | |
| SCHEMBL171599 | 0.75 | DRD4 (0.48) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL29352448 | 0.75 | DRD4 (0.48) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL7833509 | 0.75 | DRD2 (0.59) | DRD4DRD2DRD3ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212062-A1 | Morpholinone and morpholine derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-11-13 | — | — | US | disclosed |
| US-6531471-B2 | Antagonists for human alpha 1a receptors; lowering intraocular pressure; inhibiting cholesterol synthesis; relaxing lower urinary tract tissue; treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, etc. | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-03-11 | — | — | US | disclosed |
| US-6362182-B1 | HYPOTENSIVE AGENTS; ANTICHOLESTEROL AGENTS; BENIGN PROSTATIC HYPERTROPIC | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-03-26 | — | — | US | disclosed |
| US-6218390-B1 | FOR LOWERING INTRAOCULAR PRESSURE, INHIBITING CHOLESTEROL SYNTHESIS, RELAXING LOWER URINARY TRACT TISSUE, THERAPY OF BENIGN PROSTATIC HYPERPLASIA, IMPOTENCY, CARDIAC ARRHYTHMIA, SYMPATHETIC MEDIATED PAIN, MIGRAINE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212062-A1 | Morpholinone and morpholine derivatives and uses thereof | ADRA1D, ADRA1A, ADRB1 | DRD4 2816/4885DRD2 1469/4885DRD3 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.